X4 Pharmaceuticals, a biopharmaceutical company focused on treatment for rare diseases, has appointed Pauline Dufresne as Vice President, HR Business Partner. Hanold Associates’ Mayank Parikh, Sarah Kennedy and Eleanor Tetreault led the search for this role based in Boston, Massachusetts.
X4 is a mission-driven company centered around the development of treatments that have an impact on patients suffering from rare diseases. X4’s leading product is mavorixafor, a potential first-in-class treatment that is currently in a Phase 3 clinical trial. The product has demonstrated proof of concept in the treatment of WHIM syndrome, a rare, inherited, primary immunodeficiency disease. Based in Boston, Massachusetts, the company has an additional research facility in Vienna, Austria and has grown to 75 employees across all locations. X4 is publicly traded on the NASDAQ as XFOR.
Pauline previously served as a Director, Global HR Business Partner at Novartis Institutes for Biomedical Research, overseeing talent management, diversity and inclusion and leadership development. Joining X4 as the Vice President, HR Business Partner, Pauline will partner closely with the Senior Vice President of HR and HR team to expand X4’s leadership and HR talent strategies to enable the company’s continued success and growth.
